Dr. Reddy's Laboratories Ltd. (RDY)
14.09
+0.34
(+2.47%)
USD |
NYSE |
Oct 28, 14:55
Dr. Reddy's Laboratories Enterprise Value : 11.45B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 11.45B |
| October 26, 2026 | 11.45B |
| October 23, 2026 | 11.00B |
| October 22, 2026 | 11.01B |
| October 21, 2026 | 10.98B |
| October 20, 2026 | 11.04B |
| October 19, 2026 | 10.89B |
| October 16, 2026 | 10.88B |
| October 15, 2026 | 10.74B |
| October 14, 2026 | 10.61B |
| October 13, 2026 | 10.63B |
| October 12, 2026 | 10.67B |
| October 09, 2026 | 10.39B |
| October 08, 2026 | 10.16B |
| October 07, 2026 | 10.21B |
| October 06, 2026 | 10.40B |
| October 05, 2026 | 10.26B |
| October 02, 2026 | 10.20B |
| October 01, 2026 | 10.20B |
| September 30, 2026 | 10.51B |
| September 29, 2026 | 10.64B |
| September 28, 2026 | 10.36B |
| September 25, 2026 | 10.14B |
| September 24, 2026 | 10.18B |
| September 23, 2026 | 10.26B |
| Date | Value |
|---|---|
| September 22, 2026 | 10.41B |
| September 21, 2026 | 10.26B |
| September 18, 2026 | 10.09B |
| September 17, 2026 | 10.09B |
| September 16, 2026 | 9.664B |
| September 15, 2026 | 9.556B |
| September 14, 2026 | 9.856B |
| September 11, 2026 | 9.847B |
| September 10, 2026 | 9.689B |
| September 09, 2026 | 9.831B |
| September 08, 2026 | 9.831B |
| September 04, 2026 | 9.906B |
| September 03, 2026 | 9.956B |
| September 02, 2026 | 10.07B |
| September 01, 2026 | 10.07B |
| August 31, 2026 | 10.04B |
| August 28, 2026 | 10.08B |
| August 27, 2026 | 10.06B |
| August 26, 2026 | 10.11B |
| August 25, 2026 | 10.21B |
| August 24, 2026 | 10.11B |
| August 21, 2026 | 10.08B |
| August 20, 2026 | 10.02B |
| August 19, 2026 | 10.02B |
| August 18, 2026 | 10.06B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co., Ltd. | 91.63B |
| Teva Pharmaceutical Industries Ltd. | 60.28B |
| AstraZeneca PLC | 553.83B |
| ANI Pharmaceuticals, Inc. | 1.870B |
| Corcept Therapeutics, Inc. | 9.154B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 95.57M |
| Revenue (Quarterly) | 907.22M |
| Total Expenses (Quarterly) | 810.43M |
| EPS Diluted (Quarterly) | 0.1161 |
| Gross Profit Margin (Quarterly) | 48.82% |
| Profit Margin (Quarterly) | 10.53% |
| Earnings Yield | 2.58% |
| Operating Earnings Yield | 2.71% |
| Normalized Earnings Yield | 2.630 |